Doctors hands

The Section of Gynaecologic Oncology performs leading research in the field of gynaecologic oncology aiming to promote prevention and early detection, optimise oncological outcomes and reduce morbidity with an emphasis in precision medicine."

Dr Maria Kyrgiou

Head of Section

The Section of Gynaecologic Oncology runs translational research in the field of gynaecological cancer with an emphasis on prevention and personalised precision medicine. The research groups use genetic, epigenetic, microbiome and metabolic platforms to explore causes and prevention strategies for gynaecological malignancies of the cervix, endometrium, ovary, vulva and vagina. Novel technologies are investigated for the intraoperative diagnosis and treatment of gynaecological cancers. There is a focus on the use of biomarkers to predict surgical outcome.

Head of Section of Gynaecological Oncology

Key studies and research groups

  • The Cervical Cancer group - Cervical Cancer Prevention & Management: This group led by Dr Mara Kyrgiou is integrating genetic, epigenetic, microbiome and metabonomic platforms to explore what promotes cervical carcinogenesis and improve prevention, early detection and improved treatment. Genome and epigenome association studies, clinical trials and epidemiological research is a focus.
  • Cancer & Metabolism Group – Obesity & Diabetes: This group led by Dr Mara Kyrgiou is exploring the impact of obesity and metabolic disorders in the development, management and prognosis of gynaecological malignancies. The role of genital tract microbiome and the use of organoids in endometrial cancer is a focus.
  • Ovarian cancer group: This group is led by Prof Ghaem-Maghami exploring immunomics and development of immunological therapies in ovarian cancer, the use of novel technologies in intraoperative diagnosis and treatment of gynaecological cancers and the use of biomarkers to predict surgical outcome.
  • Cell Signalling Group: This group is led by Dr Nick Dibb and focuses on receptor signalling and kinase inhibitor studies in cancer & reproduction and RNA splicing and microRNA function in stem cells.
  • Fertility and Pregnancy Care After Cancer Treatment
  • Women's Cancers
  • The NOVEL trial: funded by the National Institute of Health Research is looking into the value of HPV vaccine after treatment for cervical precancer.
Dr Maria Kyrgiou

Dr Maria Kyrgiou

Head of Gynaecological Oncology

Dr Maria Kyrgiou is a Clinical Reader (Associate Professor) at Imperial College London and a Consultant Surgeon in Gynaecology and Gynaecologic Oncology at the West London Gynaecological Cancer Centre, Imperial Healthcare NHS Trust. Her main clinical interest is in gynaecologic and gynaecologic cancer surgery and minimal access surgery.

Further information on Dr Mara Kyrgiou

Research group leads